Genomic Therapy Matching in Rare and Refractory CancersFrank P. Lin, Emily Collignon, Maya Kansara et al.|JAMA Oncology|2026Cited by 6
996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14Frank Lin, D. Thomas, M. Itchins et al.|Annals of Oncology|2025Cited by 0